依达拉奉联合血栓通治疗急性脑梗死的疗效观察  

Effective Observation on Edaravone Combined with Xueshuantong in Treating Acute Cerebral Infarction

作　　者：王勤勇[1] 张芷宁[1] 王泽林[1] 范艳辉[1] 

机构地区：[1]中国人民解放军北京军区北戴河疗养院神经内科,河北秦皇岛066100

出　　处：《中国药业》2014年第20期25-26,共2页China Pharmaceuticals

摘　　要：目的观察依达拉奉联合血栓通治疗急性脑梗死的临床疗效及安全性。方法将106例急性脑梗死患者随机分为观察组和对照组,各53例。对照组患者给予注射用血栓通0.4 g静脉滴注、每日1次,观察组患者在对照组基础上给予依达拉奉注射液30 mg静脉滴注、每日1次。两组患者均治疗14 d,治疗前后分别测定患者的血浆C反应蛋白(CRP)和纤维蛋白原(Fg)水平,并进行神经功能缺损评分,比较临床疗效及安全性。结果治疗结束后两组患者血浆CRP及Fg水平、卒中量表(NIHSS)神经功能缺损评分和Barthel指数较治疗前均明显改善(P<0.05),观察组各项指标改善情况及临床疗效均显著优于对照组(P<0.05)。两组患者不良反应发生率无明显差异。结论依达拉奉联合血栓通治疗急性脑梗死疗效确切、安全可靠,值得临床推广和进一步深入研究。Objective To observe the clinical efficacy and safety of edaravone ambined with Xueshuantong in treating acute cerebral in-farction. Methods 106 patients with acute cerebral infarction were randomly divided into the observation group and the control group, 53 cases in each group. The patients in the control group were given Xueshuantong 0. 4 g by intravenous drip,once daily,while on the basis of the control group the observation group was given Eedaravone Injection 30 mg by intravenous drip,once daily. All patients in the two groups were treated for 14 d. The C reactive protein（CRP）,fibrinogen（Fg） were detected before and after treatment and the NIHSS scores were evaluated. The effect and safety were compared between the two groups. Results The clinical effect,plasma CRP and Fg ,NIHSS score and Barthel index after therapy in the two groups were significantly improved compared with before therapy （ P 〈 0. 05）,but the improvement of various indexes in the observation group were superior to those in the control group（ P 〈 0. 05）. There was no statistically significant difference in the occurrence rate of adverse reactions between the two groups. Conclusion Edar-avone combined with Xueshuantong has definite effect,safety and reliability in treating acute cerebral infarction,which is worthy of clin-ical promotion and further deep study.

关 键 词：依达拉奉 血栓通 急性脑梗死 

分 类 号：R285.6[医药卫生—中药学] R286[医药卫生—中医学]